Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

For Watson CEO Bisaro, “Operational Efficiency” Is An Industry-Wide Calling

Executive Summary

Contaminated heparin continues to create regulatory fallout worldwide, so one might think that this would not be a particularly good time to press FDA to loosen its manufacturing oversight
Advertisement

Related Content

FDA's Generic Drugs Office Faces Transition As Director Buehler Departs
Ranbaxy’s Ripples: Generic Drug Integrity Returns As Focus For Congress, FDA
Ranbaxy’s Ripples: Generic Drug Integrity Returns As Focus For Congress, FDA
QC LAB DATA MUST BE KEPT AND INVESTIGATIONS DOCUMENTED, FDAer VOGEL TELLS PDA WORKSHOP; INDUSTRY REPS URGE FDA FLEXIBILITY IN INTERPRETING BARR DECISION
QC LAB DATA MUST BE KEPT AND INVESTIGATIONS DOCUMENTED, FDAer VOGEL TELLS PDA WORKSHOP; INDUSTRY REPS URGE FDA FLEXIBILITY IN INTERPRETING BARR DECISION
Advertisement
UsernamePublicRestriction

Register

PS049784

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel